1-[8-(2-Chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-3-(ethylamino)azetidine-3-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-[8-(2-Chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-3-(ethylamino)azetidine-3-carboxamide
• 化学式: C₂₃H₂₁Cl₂N₇O
• 分子量: 482.4
• InChiKey: DDLXFJXATMJVFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] PURINE COMPOUNDS AND USES THEREOF AS CANNABINOID RECEPTOR LIGANDS<br/>[FR] COMPOSES PURINIQUES ET LEURS UTILISATIONS COMME LIGANDS DE RECEPTEURS DES CANNABINOIDES
  申请人：PFIZER PROD INC

  公开号：WO2004037823A1

  公开（公告）日：2004-05-06

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.

  本文描述了作为大麻素受体配体的化合物（I）及其在治疗与动物体内大麻素受体介导相关疾病中的用途。
• Purine compounds and uses thereof
  申请人：Pfizer Inc.

  公开号：US20040092520A1

  公开（公告）日：2004-05-13

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. 1

  本文描述了化学式为（I）的化合物，它们作为大麻素受体配体，并且在动物中治疗与大麻素受体介导的疾病相关的用途。
• Cannabinoid Receptor Ligands and Uses Thereof
  申请人：Griffith A. David

  公开号：US20060241120A1

  公开（公告）日：2006-10-26

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.

  本文介绍了一种化合物（I）的配方，其作为大麻素受体配体，并且在动物中治疗与大麻素受体介导的疾病相关的用途。
• Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
  申请人：Pfizer Inc

  公开号：US20040224962A1

  公开（公告）日：2004-11-11

  Pharmaceutical compositions are disclosed for the treatment of obesity, an overweight condition and compulsive overeating. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.

  本发明公开了用于治疗肥胖、超重和强迫性暴饮暴食的药物组合物。这些药物组合物由烟碱受体部分激动剂和 CB-1 受体拮抗剂的治疗有效组合以及药学上可接受的载体组成。还公开了使用这些化合物的方法。
• Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
  申请人：Pfizer Inc

  公开号：US20040224963A1

  公开（公告）日：2004-11-11

  Pharmaceutical compositions are disclosed for the treatment of nicotine dependence or addiction, tobacco dependence or addiction, reduction of nicotine withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse or other behavioral dependencies. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.

  本发明公开了用于治疗尼古丁依赖或成瘾、烟草依赖或成瘾、减轻尼古丁戒断症状或帮助戒烟或减少烟草使用或药物滥用或其他行为依赖的药物组合物。药物组合物由尼古丁受体部分激动剂和 CB-1 受体拮抗剂的治疗有效组合以及药学上可接受的载体组成。还公开了使用这些化合物的方法。